Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13141 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Rong Deng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Doxorubicin, Cyclophosphamide, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Polatuzumab vedotin is a CD79b‐directed antibody–drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHP) as first‐line treatment of diffuse large B‐cell lymphoma (DLBCL). To examine dosing decisions for this regimen, population pharmacokinetic (popPK) analysis, using a previously developed popPK model, and exposure–response (ER) analysis, were performed. The popPK analysis showed no clinically meaningful relationship between cycle 6 (C6) antibody‐conjugated (acMMAE)/unconjugated MMAE area under the concentration–time curve (AUC) or maximum concentration, and weight, sex, ethnicity, region, mild or moderate renal impairment, mild hepatic impairment, or other patient and disease characteristics. In the ER analysis, C6 acMMAE AUC was significantly associated with longer progression‐free and event‐free survival (both p = 0.01). An increase of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, California, USA.
- QuantPharm LLC, North Potomac, Maryland, USA.
- Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
- BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Leonid Gibiansky, Tong Lu, Dale Miles
Zitieren
APA
Deng, R., Gibiansky, L., Lu, T., Flowers, C. R., Sehn, L. H., Liu, Q., Agarwal, P., Liao, M. Z., Dere, R., Lee, C., Man, G., Hirata, J., Li, C., & Miles, D. (2024). Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13141
Vancouver
Deng R, Gibiansky L, Lu T, Flowers CR, Sehn LH, Liu Q, et al. Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13141
BibTeX
@article{Deng2024,
author = {Deng, Rong and Gibiansky, Leonid and Lu, Tong and Flowers, Christopher R and Sehn, Laurie H and Liu, Qi and Agarwal, Priya and Liao, Michael Z and Dere, Randall and Lee, Calvin and Man, Gabriel and Hirata, Jamie and Li, Chunze and Miles, Dale},
title = {Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13141}
}
EUVIMED